Amalgamated Bank Sells 532 Shares of ICU Medical, Inc. (NASDAQ:ICUI)

Amalgamated Bank trimmed its position in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 7.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,251 shares of the medical instruments supplier’s stock after selling 532 shares during the quarter. Amalgamated Bank’s holdings in ICU Medical were worth $742,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in ICUI. Vanguard Group Inc. raised its position in shares of ICU Medical by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 2,452,720 shares of the medical instruments supplier’s stock valued at $263,226,000 after acquiring an additional 11,991 shares during the period. Schroder Investment Management Group boosted its position in ICU Medical by 35.8% during the 4th quarter. Schroder Investment Management Group now owns 433,852 shares of the medical instruments supplier’s stock worth $43,272,000 after acquiring an additional 114,344 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of ICU Medical by 21.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 311,542 shares of the medical instruments supplier’s stock worth $36,996,000 after acquiring an additional 55,588 shares in the last quarter. Silvercrest Asset Management Group LLC grew its holdings in shares of ICU Medical by 109.4% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 278,436 shares of the medical instruments supplier’s stock valued at $29,882,000 after acquiring an additional 145,485 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of ICU Medical by 11.5% in the second quarter. Bank of New York Mellon Corp now owns 216,509 shares of the medical instruments supplier’s stock valued at $25,710,000 after acquiring an additional 22,310 shares during the last quarter. 96.10% of the stock is owned by institutional investors.

ICU Medical Price Performance

NASDAQ:ICUI opened at $174.47 on Friday. The firm has a market capitalization of $4.25 billion, a price-to-earnings ratio of -71.21 and a beta of 0.65. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 2.41. The stock has a fifty day moving average of $154.77 and a 200 day moving average of $124.01. ICU Medical, Inc. has a 52-week low of $78.28 and a 52-week high of $181.87.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.56. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. The business had revenue of $596.50 million for the quarter, compared to analysts’ expectations of $556.64 million. During the same quarter in the prior year, the firm earned $1.58 earnings per share. The firm’s revenue was up 8.6% on a year-over-year basis. On average, research analysts expect that ICU Medical, Inc. will post 3.76 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ICUI. Raymond James raised their price target on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a report on Thursday, September 12th. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Thursday, September 12th. Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a report on Thursday, August 8th. Finally, KeyCorp boosted their price target on ICU Medical from $136.00 to $147.00 and gave the company an “overweight” rating in a research note on Thursday, August 8th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $149.00.

Insider Activity

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $163.46, for a total transaction of $1,961,520.00. Following the transaction, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at approximately $17,096,771.78. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, VP Daniel Woolson sold 2,502 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $163.22, for a total transaction of $408,376.44. Following the sale, the vice president now owns 13,107 shares in the company, valued at $2,139,324.54. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $163.46, for a total value of $1,961,520.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at $17,096,771.78. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,552 shares of company stock valued at $4,537,802. Company insiders own 6.70% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.